Oslo, Norway, June 20th, 2022 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, is happy to announce that it has secured NOK 12mill. The capital raise together with Eurostars funding will enable Adjutec to start the non-clinical program of APC247, its new broad-spectrum β-lactamase inhibitor. The early start of the non-clinical program is an exciting milestone for the company that will secure a maximum period of market protection. The company filed a patent in 2021. The funding will also give Adjutec financial flexibility in planning of the next capital raise early 2023 to fund the clinical phase 1 program. Adjutec preclinical R&D is partly financed by three grants through the Norwegian Research Council (NRC). This important non-dilutive funding is unaffected by proposed cut-backs in future budgets of NRC.
Adjutec also looks for international funding opportunities and has expectations to upcoming calls from the CARB-X program that recently raised US$370mill to stimulate development of new products to fight antimicrobial resistance (AMR). The program is supported by The Biomedical Advanced Research and Development Authority (BARDA) and U.S. National Institute of Allergy and Infectious Diseases (NIAID), both within the US Human Health Services, and Wellcome. The CARB-X program emphasizes the US governmental commitment to support development of new AMR products to benefit the US population.
U.S. government and Wellcome commit up to an additional US$370 million to CARB-X – Carb-X (link).
“The recent capital raise among existing investors reflects the good progress of our non-clinical activities in Adjutec over the last months. Despite recent global turmoils affecting both deliveries of materials and availability of private capital, we were able to complete the capital raise as planned. Recent grants from Eurostars and the Norwegian Research Council put Adjutec is an excellent position to continue non-clinical activities and prepare for clinical trials in 2023” comments Chair of Board, Nicolaj Weiergang.
Full PR available here